Functional characteristics and membrane localization of rat multispecific organic cation transporters, OCT1 and OCT2, mediating tubular secretion of cationic drugs

被引:0
|
作者
Urakami, Y [1 ]
Okuda, M [1 ]
Masuda, S [1 ]
Saito, H [1 ]
Inui, KI [1 ]
机构
[1] Kyoto Univ Hosp, Dept Pharm, Fac Med, Sakyo Ku, Kyoto 6068507, Japan
关键词
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We have isolated a kidney-specific organic cation transporter, rat OCT2, which is distinct from rat OCT1 (Okuda M, Saito H, Urakami Y, Takano M and Inui K (1996) Biochem Biophys Res Commun 224:500-507). In our study, the functional characteristics and membrane localization of OCT1 and OCT2 were investigated by uptake studies using MDCK cells transfected with rat OCT1 or OCT2 cDNA (MDCK-OCT1 or MDCK-OCT2) and immunological studies. Tetraethylammonium (TEA) uptake by both MDCK-OCT1 and MDCK-OCT2 cells was markedly elevated when TEA was added to the basolateral medium, but not to the apical medium. Efflux of TEA from MDCK-OCT1 and MDCK-OCT2 cells was not changed by extracellular pH from 5.4 to 8.4, whereas TEA uptake by both transfectants was decreased by acidification of extracellular medium. Apparent K-m values for TEA uptake by MDCK-OCT1 and MDCK-OCT2 cells were 38 and 45 mu M, respectively. Although various hydrophilic organic cations such as 1-methyl-4-phenylpyridinium, cimetidine, quinidine, nicotine, N-1-methylnicotinamide and guanidine markedly inhibited TEA uptake by both MDCK-OCT1 and MDCK-OCT2 cells, there were no significant differences in the apparent inhibition constants [K-i] against these organic cations between both transfectants. Furthermore, immunological studies using a polyclonal antibody against OCT1 revealed that OCT1 was expressed in the basolateral membranes but not in the brush-border membranes of the rat kidney. These results suggested that both OCT1 and OCT2 are basolateral-type organic cation transporters with broad substrate specificities, mediating tubular secretion of cationic drugs.
引用
收藏
页码:800 / 805
页数:6
相关论文
共 50 条
  • [31] Cellular localization of the organic cation transporters, OCT1 and OCT2, in brain microvessel endothelial cells and its implication for MPTP transport across the blood-brain barrier and MPTP-induced dopaminergic toxicity in rodents
    Lin, Chun-Jung
    Tai, Ying
    Huang, Miao-Tzu
    Tsai, Yuan-Feen
    Hsu, Hao-Jui
    Tzen, Kai-Yuan
    Liou, Horng-Huei
    JOURNAL OF NEUROCHEMISTRY, 2010, 114 (03) : 717 - 727
  • [32] Changes of drug pharmacokinetics mediated by downregulation of kidney organic cation transporters Mate1 and Oct2 in a rat model of hyperuricemia
    Nishizawa, Kei
    Yoda, Noriaki
    Morokado, Fumi
    Komori, Hisakazu
    Nakanishi, Takeo
    Tamai, Ikumi
    PLOS ONE, 2019, 14 (04):
  • [33] Molecular Properties of Drugs Interacting with SLC22 Transporters OAT1, OAT3, OCT1, and OCT2: A Machine-Learning Approachs
    Liu, Henry C.
    Goldenberg, Anne
    Chen, Yuchen
    Lun, Christina
    Wu, Wei
    Bush, Kevin T.
    Balac, Natasha
    Rodriguez, Paul
    Abagyan, Ruben
    Nigam, Sanjay K.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2016, 359 (01): : 215 - 229
  • [34] Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity
    Yokoo, Sachiko
    Yonezawa, Atsushi
    Masuda, Satohiro
    Fukatsu, Atsushi
    Katsura, Toshiya
    Inui, Ken-Ichi
    BIOCHEMICAL PHARMACOLOGY, 2007, 74 (03) : 477 - 487
  • [35] Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3)
    Jonker, JW
    Schinkel, AH
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2004, 308 (01): : 2 - 9
  • [36] Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients
    Tarasova, Linda
    Kalnina, Ineta
    Geldnere, Kristine
    Bumbure, Alda
    Ritenberga, Rota
    Nikitina-Zake, Liene
    Fridmanis, Davids
    Vaivade, Iveta
    Pirags, Valdis
    Klovins, Janis
    PHARMACOGENETICS AND GENOMICS, 2012, 22 (09): : 659 - 666
  • [37] Obstructive cholestasis results in down-regulation and functional impairment of the organic cation transporter 1 (Oct1) in rat liver.
    Denk, GU
    Soroka, CJ
    Mennone, A
    Koepsell, H
    Beuers, U
    Boyer, JL
    HEPATOLOGY, 2003, 38 (04) : 168A - 168A
  • [38] The antiglaucoma agents brimonidine and timolol are novel substrates of the organic cation transporters OCT2 and MATE1 expressed in human eye
    Neul, C.
    Suesskind, D.
    Lang, T.
    Hofmann, U.
    Ziemssen, F.
    Schiefer, U.
    Schwab, M.
    Nies, A. T.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2016, 389 (01) : S21 - S21
  • [39] No dose adjustment of metformin or substrates of organic cation transporters (OCT)1 and OCT2 and multidrug and toxin extrusion protein (MATE)1/2K with fostemsavir coadministration based on modeling approaches
    Nguyen, Dung
    Miao, Xiusheng
    Taskar, Kunal
    Magee, Mindy
    Gorycki, Pete
    Moore, Katy
    Tai, Guoying
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2024, 12 (04):
  • [40] Genetic polymorphisms of organic cation transporters 1 (OCT1) and responses to metformin therapy in individuals with type 2 diabetes mellitus: a systematic review protocol
    Mato, Edith Pascale Mofo
    Guewo-Fokeng, Magellan
    Essop, M. Faadiel
    Owira, Peter Mark Oroma
    SYSTEMATIC REVIEWS, 2018, 7